Home › All Companies › ZURA › Annual Report

Zura Bio Ltd (ZURA) — Annual Report

AI-Powered SEC Filing Analysis

← All ZURA filings
Latest Annual Report Filed: 2026-03-19

Key Insights

  • Zura Bio Ltd appears to be an emerging biotech company with a focus on developing therapies for autoimmune and inflammatory diseases, including potential pipeline candidates like tibulizumab and crebankinog.
  • The company has entered into several licensing agreements, including with Eli Lilly and Pfizer, which could provide important sources of funding and development support for its programs.
  • Zura Bio has raised capital through various means, including private placements, warrants, and an at-the-market offering, indicating ongoing funding needs as it advances its R&D efforts.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-19. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Zura Bio Ltd

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.